FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Authors

Chiara Cremolini

Published

September 1, 2015

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Oncology

Topics

DOI

10.1016/s1470-2045(15)00122-9

Other Formats

PDF

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Authors

Chiara Cremolini

Published

September 1, 2015

Add a comment...

Supporters

Support the authors with ResearchCoin

Journal

The Lancet Oncology

Topics

DOI

10.1016/s1470-2045(15)00122-9

Other Formats

PDF

Paper

Paper

Paper

Paper

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Supporters

Journal

Topics

DOI

Other Formats

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Supporters

Journal

Topics

DOI

Other Formats

Supporters

Journal

Topics

DOI

Other Formats